Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pradip De

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
American Journal of Cancer Research|July 12, 2021
A tipping-point for apoptosis following dual inhibition of HER2 signaling network by T-DM1 plus GDC-0980 maximizes anti-tumor efficacyNandini Dey, Jennifer Aske, Xiaoqian Lin, et al.
Plos One|October 22, 2013
Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent mannerNandini Dey, Brandon Young, Mark Abramovitz, et al.
Cureus|September 1, 2017
Utilizing Tumor and Plasma Liquid Biopsy in Treatment Decision Making for an Estrogen Receptor-Positive Advanced Breast Cancer PatientBing Xu, Amy Krie, Pradip De, et al.
Neoplasia (New York, N.Y.)|February 25, 2014
Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-nessPradip De, Yuling Sun, Jennifer H Carlson, et al.
American Journal of Cancer Research|May 18, 2016
Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancersNandini Dey, Yuliang Sun, Jennifer H Carlson, et al.
Cancer Research|March 15, 2008
The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migrationNandini Dey, Hal E Crosswell, Pradip De, et al.
Journal of Hematology & Oncology|August 28, 2022
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional responseHanna E Persha, Shumei Kato, Pradip De, et al.
BMC Medicine|February 18, 2024
Neuregulin-1 and ALS19 (ERBB4): at the crossroads of amyotrophic lateral sclerosis and cancerJacob J Adashek, Chinmayi Pandya, Nicholas J Maragakis, et al.
Blood|August 15, 2002
SHP-1 regulates Fcgamma receptor-mediated phagocytosis and the activation of RACAnita M Kant, Pradip De, Xiaodong Peng, et al.
The Journal of Biological Chemistry|November 13, 2004
Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinaseKyung D Moon, Carol B Post, Donald L Durden, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
American Journal of Cancer Research|July 12, 2021
A tipping-point for apoptosis following dual inhibition of HER2 signaling network by T-DM1 plus GDC-0980 maximizes anti-tumor efficacyNandini Dey, Jennifer Aske, Xiaoqian Lin, et al.
Plos One|October 22, 2013
Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent mannerNandini Dey, Brandon Young, Mark Abramovitz, et al.
Cureus|September 1, 2017
Utilizing Tumor and Plasma Liquid Biopsy in Treatment Decision Making for an Estrogen Receptor-Positive Advanced Breast Cancer PatientBing Xu, Amy Krie, Pradip De, et al.
Neoplasia (New York, N.Y.)|February 25, 2014
Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-nessPradip De, Yuling Sun, Jennifer H Carlson, et al.
American Journal of Cancer Research|May 18, 2016
Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancersNandini Dey, Yuliang Sun, Jennifer H Carlson, et al.
Cancer Research|March 15, 2008
The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migrationNandini Dey, Hal E Crosswell, Pradip De, et al.
Journal of Hematology & Oncology|August 28, 2022
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional responseHanna E Persha, Shumei Kato, Pradip De, et al.
BMC Medicine|February 18, 2024
Neuregulin-1 and ALS19 (ERBB4): at the crossroads of amyotrophic lateral sclerosis and cancerJacob J Adashek, Chinmayi Pandya, Nicholas J Maragakis, et al.
Blood|August 15, 2002
SHP-1 regulates Fcgamma receptor-mediated phagocytosis and the activation of RACAnita M Kant, Pradip De, Xiaodong Peng, et al.
The Journal of Biological Chemistry|November 13, 2004
Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinaseKyung D Moon, Carol B Post, Donald L Durden, et al.
Pageof 7